Free Trial

Bicycle Therapeutics (BCYC) Financials

Bicycle Therapeutics logo
$8.53 +0.33 (+3.99%)
As of 12:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Bicycle Therapeutics

Annual Income Statements for Bicycle Therapeutics

This table shows Bicycle Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-169 -181 -113
Consolidated Net Income / (Loss)
-169 -181 -113
Net Income / (Loss) Continuing Operations
-169 -181 -113
Total Pre-Tax Income
-174 -179 -114
Total Operating Income
-210 -190 -117
Total Gross Profit
35 27 14
Total Revenue
35 27 14
Operating Revenue
35 27 14
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
245 217 131
Selling, General & Admin Expense
72 60 50
Research & Development Expense
173 156 82
Total Other Income / (Expense), net
36 11 2.41
Interest Expense
2.68 3.26 3.34
Interest & Investment Income
34 14 5.76
Other Income / (Expense), net
4.48 0.00 0.00
Income Tax Expense
-4.77 1.46 -1.52
Basic Earnings per Share
($2.90) ($5.08) ($3.80)
Weighted Average Basic Shares Outstanding
58.21M 35.59M 29.66M
Diluted Earnings per Share
($2.90) ($5.08) ($3.80)
Weighted Average Diluted Shares Outstanding
58.21M 35.59M 29.66M
Weighted Average Basic & Diluted Shares Outstanding
69.20M 42.59M 30.02M
Cash Dividends to Common per Share
$0.00 $0.00 $0.00

Quarterly Income Statements for Bicycle Therapeutics

This table shows Bicycle Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-50 -53 -40 -27 -53 -46 -43 -39 -30 -28
Consolidated Net Income / (Loss)
-52 -51 -40 -27 -49 -50 -43 -39 -30 -28
Net Income / (Loss) Continuing Operations
-52 -51 -40 -27 -49 -50 -43 -39 -30 -28
Total Pre-Tax Income
-53 -54 -40 -27 -49 -48 -43 -40 -30 -29
Total Operating Income
-68 -64 -47 -32 -54 -51 -43 -42 -32 -30
Total Gross Profit
3.71 2.68 9.36 20 5.33 5.35 11 4.90 3.19 3.04
Total Revenue
3.71 2.68 9.36 20 5.33 5.35 11 4.90 3.19 3.04
Operating Revenue
3.71 2.68 9.36 20 5.33 5.35 11 4.90 3.19 3.04
Total Operating Expenses
71 67 56 51 60 56 55 47 35 33
Selling, General & Admin Expense
22 18 16 16 15 16 15 14 11 10
Research & Development Expense
50 48 40 35 45 40 40 32 25 23
Total Other Income / (Expense), net
15 9.60 6.95 4.80 5.47 3.17 -0.02 2.12 1.79 1.17
Interest Expense
0.05 0.99 0.82 0.82 0.82 0.81 0.82 0.81 0.83 0.82
Interest & Investment Income
10 11 7.77 5.62 6.28 3.99 0.81 2.93 2.64 1.99
Income Tax Expense
-1.08 -3.45 0.12 -0.35 0.32 2.27 -0.52 -0.62 -0.42 -0.24
Basic Earnings per Share
($0.77) ($0.74) ($0.77) ($0.62) ($1.11) ($1.26) ($1.41) ($1.30) ($1.01) ($0.96)
Weighted Average Basic Shares Outstanding
58.21M 68.99M 51.99M 42.56M 35.59M 39.58M 30.19M 30.00M 29.66M 29.68M
Diluted Earnings per Share
($0.77) ($0.74) ($0.77) ($0.62) ($1.11) ($1.26) ($1.41) ($1.30) ($1.01) ($0.96)
Weighted Average Diluted Shares Outstanding
58.21M 68.99M 51.99M 42.56M 35.59M 39.58M 30.19M 30.00M 29.66M 29.68M
Weighted Average Basic & Diluted Shares Outstanding
69.20M 69.05M 68.99M 42.78M 42.59M 42.42M 41.42M 30.04M 30.02M 29.69M

Annual Cash Flow Statements for Bicycle Therapeutics

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
353 188 -100
Net Cash From Operating Activities
-165 -61 -86
Net Cash From Continuing Operating Activities
-165 -61 -86
Net Income / (Loss) Continuing Operations
-169 -181 -113
Consolidated Net Income / (Loss)
-169 -181 -113
Depreciation Expense
7.17 6.55 3.69
Non-Cash Adjustments To Reconcile Net Income
28 34 20
Changes in Operating Assets and Liabilities, net
-31 79 2.71
Net Cash From Investing Activities
-1.24 -2.93 -19
Net Cash From Continuing Investing Activities
-1.24 -2.93 -19
Purchase of Property, Plant & Equipment
-1.24 -2.93 -19
Net Cash From Financing Activities
520 250 6.69
Net Cash From Continuing Financing Activities
520 250 6.69
Repayment of Debt
-32 0.00 0.00
Issuance of Common Equity
544 249 5.70
Other Financing Activities, net
7.53 0.68 0.99
Effect of Exchange Rate Changes
-0.69 1.35 -1.12
Cash Interest Paid
1.40 2.75 2.79
Cash Income Taxes Paid
0.79 0.56 2.23

Quarterly Cash Flow Statements for Bicycle Therapeutics

This table details how cash moves in and out of Bicycle Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-11 -71 504 -69 -46 232 47 -45 -22 -11
Net Cash From Operating Activities
-9.40 -40 -45 -71 -47 -1.03 34 -46 -30 -5.87
Net Cash From Continuing Operating Activities
-9.40 -40 -45 -71 -47 -1.03 34 -46 -30 -5.87
Net Income / (Loss) Continuing Operations
-52 -51 -40 -27 -49 -50 -43 -39 -30 -28
Consolidated Net Income / (Loss)
-52 -51 -40 -27 -49 -50 -43 -39 -30 -28
Depreciation Expense
1.70 2.17 1.64 1.66 1.65 1.69 1.65 1.56 1.39 1.26
Non-Cash Adjustments To Reconcile Net Income
26 3.80 3.93 -5.56 3.76 3.58 25 1.22 1.68 7.90
Changes in Operating Assets and Liabilities, net
15 5.00 -10 -40 -3.60 44 50 -10 -3.40 13
Net Cash From Investing Activities
-0.37 -0.44 -0.42 -0.01 -0.05 -0.50 -0.28 -2.10 -1.45 -2.98
Net Cash From Continuing Investing Activities
-0.37 -0.44 -0.42 -0.01 -0.05 -0.50 -0.28 -2.10 -1.45 -2.98
Purchase of Property, Plant & Equipment
-0.37 -0.44 -0.42 -0.01 -0.05 -0.50 -0.28 -2.10 -1.45 -2.98
Net Cash From Financing Activities
0.20 -32 550 1.87 0.39 235 12 2.72 5.89 0.16
Net Cash From Continuing Financing Activities
0.20 -32 550 1.87 0.39 235 12 2.72 5.89 0.16
Repayment of Debt
-0.04 - - - - - - - - -
Other Financing Activities, net
0.25 0.91 4.50 1.87 0.38 0.14 0.17 0.00 0.19 0.16
Effect of Exchange Rate Changes
-1.78 1.70 -0.19 -0.42 1.29 -0.90 0.51 0.45 3.55 -2.60
Cash Interest Paid
0.02 0.23 0.46 0.69 0.69 0.69 0.69 0.68 0.69 0.71

Annual Balance Sheets for Bicycle Therapeutics

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
957 595 411
Total Current Assets
929 562 369
Cash & Equivalents
880 526 339
Prepaid Expenses
13 11 9.02
Other Current Assets
36 24 19
Plant, Property, & Equipment, net
9.52 15 19
Total Noncurrent Assets
19 19 22
Other Noncurrent Operating Assets
19 19 22
Total Liabilities & Shareholders' Equity
957 595 411
Total Liabilities
164 224 140
Total Current Liabilities
67 70 53
Accounts Payable
16 13 6.47
Accrued Expenses
41 32 26
Current Deferred Revenue
10 25 20
Total Noncurrent Liabilities
97 155 86
Long-Term Debt
0.00 31 30
Noncurrent Deferred Revenue
91 110 41
Other Noncurrent Operating Liabilities
5.11 14 15
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
793 371 271
Total Preferred & Common Equity
793 371 271
Total Common Equity
793 371 271
Common Stock
1,474 884 601
Retained Earnings
-681 -512 -331
Accumulated Other Comprehensive Income / (Loss)
0.12 -1.30 0.39

Quarterly Balance Sheets for Bicycle Therapeutics

This table presents Bicycle Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
997 1,057 547 639 454 429 417
Total Current Assets
966 1,028 516 603 408 381 381
Cash & Equivalents
891 961 457 572 340 294 361
Prepaid Expenses
17 20 20 14 10 11 8.45
Other Current Assets
58 46 39 17 13 27 11
Plant, Property, & Equipment, net
12 12 13 16 18 18 16
Total Noncurrent Assets
19 18 18 20 28 29 20
Other Noncurrent Operating Assets
19 18 18 20 28 29 20
Total Liabilities & Shareholders' Equity
997 1,057 547 639 454 429 417
Total Liabilities
166 184 191 223 234 186 128
Total Current Liabilities
56 70 50 70 72 53 42
Accounts Payable
5.71 7.45 7.06 8.49 5.25 2.81 7.06
Accrued Expenses
39 28 26 34 37 25 18
Current Deferred Revenue
11 12 16 27 30 25 16
Total Noncurrent Liabilities
109 114 142 153 162 133 86
Long-Term Debt
0.00 8.51 31 31 31 30 30
Noncurrent Deferred Revenue
98 94 98 108 115 84 42
Other Noncurrent Operating Liabilities
11 11 13 15 16 18 14
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
831 874 356 416 220 243 289
Total Preferred & Common Equity
831 874 356 416 220 243 289
Total Common Equity
831 874 356 416 220 243 289
Common Stock
1,463 1,453 895 876 634 613 590
Retained Earnings
-629 -578 -538 -463 -413 -370 -301
Accumulated Other Comprehensive Income / (Loss)
-3.19 -1.09 -0.78 2.89 -0.88 0.07 0.53

Annual Metrics And Ratios for Bicycle Therapeutics

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
30.76% 86.52% 23.65%
EBITDA Growth
-8.08% -62.35% -75.93%
EBIT Growth
-8.13% -62.83% -77.78%
NOPAT Growth
-10.49% -62.83% -77.78%
Net Income Growth
6.44% -60.28% -68.69%
EPS Growth
42.91% -33.68% -42.32%
Operating Cash Flow Growth
-171.70% 29.59% -482.07%
Free Cash Flow Firm Growth
-300.74% 56.45% -1,028.75%
Invested Capital Growth
30.72% -227.92% 39.16%
Revenue Q/Q Growth
-4.40% 8.64% -3.89%
EBITDA Q/Q Growth
-4.70% -13.46% -13.24%
EBIT Q/Q Growth
-4.56% -13.12% -13.85%
NOPAT Q/Q Growth
-6.84% -13.12% -13.85%
Net Income Q/Q Growth
-1.66% -11.84% -11.85%
EPS Q/Q Growth
10.49% -2.01% -11.76%
Operating Cash Flow Q/Q Growth
18.70% -38.90% -30.00%
Free Cash Flow Firm Q/Q Growth
8.81% -36.57% -19.39%
Invested Capital Q/Q Growth
-44.51% 0.53% 8.88%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-561.93% -679.86% -781.06%
Operating Margin
-594.96% -704.13% -806.56%
EBIT Margin
-582.27% -704.13% -806.56%
Profit (Net Income) Margin
-479.18% -669.72% -779.35%
Tax Burden Percent
97.26% 100.81% 98.67%
Interest Burden Percent
84.62% 94.35% 97.93%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-29.04% -56.31% -36.53%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-26.46% -37.76% -26.20%
Return on Assets (ROA)
-21.78% -35.92% -25.32%
Return on Common Equity (ROCE)
-29.04% -56.31% -36.53%
Return on Equity Simple (ROE_SIMPLE)
-21.31% -48.71% -41.63%
Net Operating Profit after Tax (NOPAT)
-147 -133 -82
NOPAT Margin
-416.47% -492.89% -564.59%
Net Nonoperating Expense Percent (NNEP)
-3.22% -11.86% -8.66%
Return On Investment Capital (ROIC_SIMPLE)
-18.52% -33.11% -27.12%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
204.62% 224.00% 342.30%
R&D to Revenue
490.34% 580.13% 564.26%
Operating Expenses to Revenue
694.96% 804.13% 906.56%
Earnings before Interest and Taxes (EBIT)
-205 -190 -117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-198 -183 -113
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.22 2.07 3.25
Price to Tangible Book Value (P/TBV)
1.22 2.07 3.25
Price to Revenue (P/Rev)
27.40 28.43 60.76
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
2.47 10.06 39.41
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.08 0.11
Long-Term Debt to Equity
0.00 0.08 0.11
Financial Leverage
-1.18 -1.25 -1.16
Leverage Ratio
1.33 1.57 1.44
Compound Leverage Factor
1.13 1.48 1.41
Debt to Total Capital
0.00% 7.64% 10.07%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 7.64% 10.07%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 92.36% 89.93%
Debt to EBITDA
0.00 -0.17 -0.27
Net Debt to EBITDA
0.00 2.70 2.73
Long-Term Debt to EBITDA
0.00 -0.17 -0.27
Debt to NOPAT
0.00 -0.23 -0.37
Net Debt to NOPAT
0.00 3.73 3.78
Long-Term Debt to NOPAT
0.00 -0.23 -0.37
Altman Z-Score
2.95 0.83 2.66
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
13.81 8.08 6.92
Quick Ratio
13.08 7.57 6.40
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-185 -46 -106
Operating Cash Flow to CapEx
-13,337.98% -2,069.92% -453.53%
Free Cash Flow to Firm to Interest Expense
-69.02 -14.17 -31.74
Operating Cash Flow to Interest Expense
-61.37 -18.58 -25.75
Operating Cash Flow Less CapEx to Interest Expense
-61.83 -19.48 -31.43
Efficiency Ratios
- - -
Asset Turnover
0.05 0.05 0.03
Accounts Receivable Turnover
0.00 0.00 9.50
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
2.94 1.60 1.30
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 38.42
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 38.42
Capital & Investment Metrics
- - -
Invested Capital
-86 -125 -38
Invested Capital Turnover
-0.33 -0.33 -0.29
Increase / (Decrease) in Invested Capital
38 -87 24
Enterprise Value (EV)
87 271 570
Market Capitalization
967 767 879
Book Value per Share
$11.49 $8.74 $9.12
Tangible Book Value per Share
$11.49 $8.74 $9.12
Total Capital
793 402 301
Total Debt
0.00 31 30
Total Long-Term Debt
0.00 31 30
Net Debt
-880 -496 -309
Capital Expenditures (CapEx)
1.24 2.93 19
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-18 -34 -23
Debt-free Net Working Capital (DFNWC)
861 492 316
Net Working Capital (NWC)
861 492 316
Net Nonoperating Expense (NNE)
22 48 31
Net Nonoperating Obligations (NNO)
-880 -496 -309
Total Depreciation and Amortization (D&A)
7.17 6.55 3.69
Debt-free, Cash-free Net Working Capital to Revenue
-51.44% -126.38% -159.81%
Debt-free Net Working Capital to Revenue
2,441.89% 1,825.07% 2,185.17%
Net Working Capital to Revenue
2,441.89% 1,825.07% 2,185.17%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($2.90) ($5.08) ($3.80)
Adjusted Weighted Average Basic Shares Outstanding
58.21M 35.59M 29.66M
Adjusted Diluted Earnings per Share
($2.90) ($5.08) ($3.80)
Adjusted Weighted Average Diluted Shares Outstanding
58.21M 35.59M 29.66M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
69.20M 42.59M 30.02M
Normalized Net Operating Profit after Tax (NOPAT)
-147 -133 -82
Normalized NOPAT Margin
-416.47% -492.89% -564.59%
Pre Tax Income Margin
-492.69% -664.32% -789.88%
Debt Service Ratios
- - -
EBIT to Interest Expense
-76.53 -58.21 -34.88
NOPAT to Interest Expense
-54.74 -40.75 -24.42
EBIT Less CapEx to Interest Expense
-76.99 -59.11 -40.56
NOPAT Less CapEx to Interest Expense
-55.20 -41.65 -30.10
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Bicycle Therapeutics

This table displays calculated financial ratios and metrics derived from Bicycle Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
-30.44% -50.00% -17.86% 298.90% 67.38% 76.05% 160.32% 26.84% -15.54% -29.84%
EBITDA Growth
-25.44% -25.59% -8.52% 25.31% -70.58% -72.34% -55.58% -49.27% -74.98% -104.16%
EBIT Growth
-24.76% -25.69% -8.18% 24.13% -68.37% -70.69% -58.09% -52.66% -78.72% -108.19%
NOPAT Growth
-24.76% -25.69% -8.20% 24.13% -68.37% -70.69% -57.92% -52.66% -78.72% -108.19%
Net Income Growth
-5.61% -1.81% 6.55% 32.00% -63.78% -76.03% -58.80% -41.72% -66.20% -93.13%
EPS Growth
30.63% 41.27% 45.39% 52.31% -9.90% -31.25% -56.67% -39.78% -65.57% -62.71%
Operating Cash Flow Growth
80.13% -3,786.05% -230.89% -52.70% -56.02% 82.54% 244.90% -75.80% -190.46% -127.03%
Free Cash Flow Firm Growth
-275.71% -329.17% -331.71% 149.37% 203.67% 226.63% 290.21% -1,648.51% -296.74% -264.73%
Invested Capital Growth
30.72% 52.31% 36.94% -246.66% -227.92% -200.41% -187.59% 57.04% 39.16% 29.15%
Revenue Q/Q Growth
38.57% -71.41% -52.07% 266.35% -0.39% -53.04% 132.78% 53.72% 4.77% -30.56%
EBITDA Q/Q Growth
-6.95% -37.03% -49.73% 42.83% -7.07% -18.40% -3.05% -30.56% -8.18% -6.89%
EBIT Q/Q Growth
-5.98% -36.87% -47.08% 41.52% -6.77% -17.80% -3.15% -29.78% -8.24% -9.11%
NOPAT Q/Q Growth
-5.98% -36.87% -47.08% 41.52% -6.77% -17.83% -3.13% -29.78% -8.24% -9.01%
Net Income Q/Q Growth
-2.07% -27.60% -49.88% 45.90% 1.60% -17.12% -9.06% -30.31% -5.75% -5.66%
EPS Q/Q Growth
-4.05% 3.90% -24.19% 44.14% 11.90% 10.64% -8.46% -28.71% -5.21% -6.67%
Operating Cash Flow Q/Q Growth
76.41% 10.74% 37.03% -49.87% -4,513.46% -103.01% 173.47% -53.13% -416.25% 75.05%
Free Cash Flow Firm Q/Q Growth
22.32% -67.58% -337.57% -43.18% 1.32% 69.43% 150.62% -19.32% -23.75% -154.51%
Invested Capital Q/Q Growth
-44.51% -5.63% 19.25% 43.79% 0.53% -39.67% -343.90% 46.83% 8.88% -33.71%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-1,778.83% -2,304.71% -480.79% -153.91% -986.33% -917.54% -363.91% -822.02% -967.82% -937.34%
Operating Margin
-1,824.78% -2,385.87% -498.31% -162.40% -1,017.35% -949.12% -378.27% -853.82% -1,011.33% -978.91%
EBIT Margin
-1,824.78% -2,385.87% -498.31% -162.40% -1,017.35% -949.12% -378.35% -853.82% -1,011.33% -978.91%
Profit (Net Income) Margin
-1,398.44% -1,898.43% -425.30% -136.01% -921.01% -932.32% -373.81% -797.88% -941.22% -932.47%
Tax Burden Percent
97.96% 93.64% 100.29% 98.70% 100.66% 104.77% 98.80% 98.44% 98.62% 99.17%
Interest Burden Percent
78.23% 84.97% 85.10% 84.86% 89.94% 93.76% 100.00% 94.93% 94.37% 96.06%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-29.04% -26.67% -30.24% -56.13% -56.31% -45.80% -52.68% -43.32% -36.53% -43.79%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-82.94% -107.66% -26.09% -13.85% -54.56% -44.64% -18.94% -29.79% -32.85% -42.18%
Return on Assets (ROA)
-63.56% -85.66% -22.27% -11.60% -49.40% -43.85% -18.71% -27.84% -30.58% -40.18%
Return on Common Equity (ROCE)
-29.04% -26.67% -30.24% -56.13% -56.31% -45.80% -52.68% -43.32% -36.53% -43.79%
Return on Equity Simple (ROE_SIMPLE)
0.00% -20.01% -18.93% -47.23% 0.00% -38.83% -63.60% -51.08% 0.00% -34.81%
Net Operating Profit after Tax (NOPAT)
-47 -45 -33 -22 -38 -36 -30 -29 -23 -21
NOPAT Margin
-1,277.35% -1,670.11% -348.82% -113.68% -712.15% -664.39% -264.79% -597.67% -707.93% -685.24%
Net Nonoperating Expense Percent (NNEP)
-0.65% -0.85% -1.15% -1.27% -2.77% -3.29% -3.81% -3.06% -2.07% -2.68%
Return On Investment Capital (ROIC_SIMPLE)
-5.97% - - - -9.45% - - - -7.49% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
582.34% 682.25% 170.38% 83.88% 278.92% 304.20% 129.75% 295.92% 335.23% 330.49%
R&D to Revenue
1,342.45% 1,803.62% 427.94% 178.52% 838.44% 744.92% 348.51% 657.90% 776.11% 748.42%
Operating Expenses to Revenue
1,924.78% 2,485.87% 598.31% 262.40% 1,117.35% 1,049.12% 478.27% 953.82% 1,111.33% 1,078.91%
Earnings before Interest and Taxes (EBIT)
-68 -64 -47 -32 -54 -51 -43 -42 -32 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-66 -62 -45 -30 -53 -49 -41 -40 -31 -28
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.22 1.88 0.99 2.97 2.07 2.00 3.48 2.63 3.25 2.38
Price to Tangible Book Value (P/TBV)
1.22 1.88 0.99 2.97 2.07 2.00 3.48 2.63 3.25 2.38
Price to Revenue (P/Rev)
27.40 42.31 21.88 25.39 28.43 33.51 34.05 41.20 60.76 45.87
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
2.47 18.17 0.00 15.14 10.06 11.71 20.29 24.20 39.41 23.86
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.04 0.09 0.08 0.07 0.14 0.13 0.11 0.10
Long-Term Debt to Equity
0.00 0.00 0.01 0.09 0.08 0.07 0.14 0.13 0.11 0.10
Financial Leverage
-1.18 -1.15 -1.13 -1.15 -1.25 -1.24 -1.23 -1.12 -1.16 -1.22
Leverage Ratio
1.33 1.31 1.38 1.63 1.57 1.50 1.69 1.55 1.44 1.52
Compound Leverage Factor
1.04 1.11 1.18 1.38 1.41 1.40 1.69 1.47 1.36 1.46
Debt to Total Capital
0.00% 0.00% 3.42% 7.96% 7.64% 6.85% 12.18% 11.12% 10.07% 9.46%
Short-Term Debt to Total Capital
0.00% 0.00% 2.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.94% 7.96% 7.64% 6.85% 12.18% 11.12% 10.07% 9.46%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 96.58% 92.04% 92.36% 93.15% 87.82% 88.88% 89.93% 90.54%
Debt to EBITDA
0.00 0.00 -0.17 -0.18 -0.17 -0.19 -0.22 -0.24 -0.27 -0.30
Net Debt to EBITDA
0.00 0.00 5.26 2.46 2.70 3.35 2.20 2.09 2.73 3.32
Long-Term Debt to EBITDA
0.00 0.00 -0.05 -0.18 -0.17 -0.19 -0.22 -0.24 -0.27 -0.30
Debt to NOPAT
0.00 0.00 -0.24 -0.24 -0.23 -0.26 -0.30 -0.33 -0.37 -0.42
Net Debt to NOPAT
0.00 0.00 7.25 3.39 3.73 4.61 3.01 2.87 3.78 4.62
Long-Term Debt to NOPAT
0.00 0.00 -0.07 -0.24 -0.23 -0.26 -0.30 -0.33 -0.37 -0.42
Altman Z-Score
3.43 5.69 3.04 2.85 1.58 2.01 1.32 1.49 3.34 3.01
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
13.81 17.13 14.77 10.42 8.08 8.65 5.65 7.19 6.92 9.18
Quick Ratio
13.08 15.79 13.81 9.23 7.57 8.20 5.33 6.49 6.40 8.70
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-86 -110 -66 28 49 48 28 -56 -47 -38
Operating Cash Flow to CapEx
-2,553.26% -9,156.78% -10,625.48% -590,575.00% -92,721.57% -204.18% 12,309.03% -2,211.10% -2,093.16% -196.75%
Free Cash Flow to Firm to Interest Expense
-1,648.02 -111.78 -79.90 33.75 59.48 59.14 34.61 -69.47 -56.95 -46.53
Operating Cash Flow to Interest Expense
-180.69 -40.36 -54.16 -86.32 -57.67 -1.26 41.53 -57.44 -36.69 -7.19
Operating Cash Flow Less CapEx to Interest Expense
-187.77 -40.80 -54.67 -86.34 -57.73 -1.88 41.19 -60.04 -38.45 -10.84
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.05 0.05 0.05 0.09 0.05 0.05 0.05 0.03 0.03 0.04
Accounts Receivable Turnover
0.00 0.00 1.75 0.00 0.00 0.00 0.82 0.00 9.50 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
2.94 2.72 2.71 2.68 1.60 1.56 1.31 1.14 1.30 1.61
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 209.01 0.00 0.00 0.00 446.48 0.00 38.42 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 209.01 0.00 0.00 0.00 446.48 0.00 38.42 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-86 -60 -57 -70 -125 -125 -90 -20 -38 -42
Invested Capital Turnover
-0.33 -0.40 -0.54 -0.92 -0.33 -0.30 -0.37 -0.46 -0.29 -0.30
Increase / (Decrease) in Invested Capital
38 66 33 -50 -87 -84 -59 27 24 17
Enterprise Value (EV)
87 670 -65 630 271 291 457 375 570 359
Market Capitalization
967 1,561 866 1,056 767 832 767 639 879 690
Book Value per Share
$11.49 $12.05 $20.43 $8.37 $8.74 $10.04 $7.33 $8.10 $9.12 $9.75
Tangible Book Value per Share
$11.49 $12.05 $20.43 $8.37 $8.74 $10.04 $7.33 $8.10 $9.12 $9.75
Total Capital
793 831 905 387 402 447 251 274 301 320
Total Debt
0.00 0.00 31 31 31 31 31 30 30 30
Total Long-Term Debt
0.00 0.00 8.51 31 31 31 31 30 30 30
Net Debt
-880 -891 -930 -426 -496 -541 -310 -263 -309 -331
Capital Expenditures (CapEx)
0.37 0.44 0.42 0.01 0.05 0.50 0.28 2.10 1.45 2.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-18 19 20 9.46 -34 -39 -4.27 34 -23 -22
Debt-free Net Working Capital (DFNWC)
861 910 981 466 492 533 336 328 316 340
Net Working Capital (NWC)
861 910 959 466 492 533 336 328 316 340
Net Nonoperating Expense (NNE)
4.49 6.11 7.16 4.36 11 14 12 9.80 7.43 7.52
Net Nonoperating Obligations (NNO)
-880 -891 -930 -426 -496 -541 -310 -263 -309 -331
Total Depreciation and Amortization (D&A)
1.70 2.17 1.64 1.66 1.65 1.69 1.65 1.56 1.39 1.26
Debt-free, Cash-free Net Working Capital to Revenue
-51.44% 51.30% 49.74% 22.72% -126.38% -156.21% -18.96% 222.23% -159.81% -144.43%
Debt-free Net Working Capital to Revenue
2,441.89% 2,465.69% 2,479.02% 1,121.01% 1,825.07% 2,147.81% 1,492.87% 2,117.93% 2,185.17% 2,257.51%
Net Working Capital to Revenue
2,441.89% 2,465.69% 2,422.41% 1,121.01% 1,825.07% 2,147.81% 1,492.87% 2,117.93% 2,185.17% 2,257.51%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.77) ($0.74) ($0.77) ($0.62) ($1.11) ($1.26) ($1.41) ($1.30) ($1.01) ($0.96)
Adjusted Weighted Average Basic Shares Outstanding
58.21M 68.99M 51.99M 42.56M 35.59M 39.58M 30.19M 30.00M 29.66M 29.68M
Adjusted Diluted Earnings per Share
($0.77) ($0.74) ($0.77) ($0.62) ($1.11) ($1.26) ($1.41) ($1.30) ($1.01) ($0.96)
Adjusted Weighted Average Diluted Shares Outstanding
58.21M 68.99M 51.99M 42.56M 35.59M 39.58M 30.19M 30.00M 29.66M 29.68M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
69.20M 69.05M 68.99M 42.78M 42.59M 42.42M 41.42M 30.04M 30.02M 29.69M
Normalized Net Operating Profit after Tax (NOPAT)
-47 -45 -33 -22 -38 -36 -30 -29 -23 -21
Normalized NOPAT Margin
-1,277.35% -1,670.11% -348.82% -113.68% -712.15% -664.39% -264.79% -597.67% -707.93% -685.24%
Pre Tax Income Margin
-1,427.62% -2,027.28% -424.07% -137.80% -915.01% -889.87% -378.35% -810.50% -954.41% -940.30%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-1,301.21 -64.69 -56.61 -38.63 -66.14 -62.40 -52.52 -51.74 -39.00 -36.42
NOPAT to Interest Expense
-910.85 -45.28 -39.63 -27.04 -46.30 -43.68 -36.76 -36.22 -27.30 -25.50
EBIT Less CapEx to Interest Expense
-1,308.29 -65.13 -57.12 -38.65 -66.20 -63.02 -52.86 -54.33 -40.75 -40.08
NOPAT Less CapEx to Interest Expense
-917.93 -45.72 -40.14 -27.06 -46.36 -44.30 -37.09 -38.81 -29.05 -29.15
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Bicycle Therapeutics' Financials

When does Bicycle Therapeutics's financial year end?

According to the most recent income statement we have on file, Bicycle Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bicycle Therapeutics' net income changed over the last 2 years?

Bicycle Therapeutics' net income appears to be on an upward trend, with a most recent value of -$169.03 million in 2024, rising from -$112.72 million in 2022. The previous period was -$180.66 million in 2023. See Bicycle Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Bicycle Therapeutics's operating income?
Bicycle Therapeutics's total operating income in 2024 was -$209.87 million, based on the following breakdown:
  • Total Gross Profit: $35.28 million
  • Total Operating Expenses: $245.15 million
How has Bicycle Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' total revenue changed from $14.46 million in 2022 to $35.28 million in 2024, a change of 143.9%.

How much debt does Bicycle Therapeutics have?

Bicycle Therapeutics' total liabilities were at $163.81 million at the end of 2024, a 27.0% decrease from 2023, and a 17.2% increase since 2022.

How much cash does Bicycle Therapeutics have?

In the past 2 years, Bicycle Therapeutics' cash and equivalents has ranged from $339.15 million in 2022 to $879.52 million in 2024, and is currently $879.52 million as of their latest financial filing in 2024.

How has Bicycle Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Bicycle Therapeutics' book value per share changed from 9.12 in 2022 to 11.49 in 2024, a change of 25.9%.



This page (NASDAQ:BCYC) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners